![](/wp-content/uploads/2018/10/xZtU0TtBTIWnZ3eKZxIL.png)
$599
Semaglutide Positive Ph2 NASH Data; Novo Q1 ’20 Earnings Update
Novo Nordisk hosted its Q1 ’20 earnings call (press release; slides) and provided updates to its diabetes business including the ongoing launch of Rybelsus (oral semaglutide) and new Ph2 semaglutide NASH topline data. Unsurprisingly, much of the Q1 ’20 prepared remarks and Q&A were focused on NASH. Below, FENIX provides highlights from the call and additional thoughts on Novo’s PCSK9i/basal insulin hybrid approach.